Clinical Trials on Sarcomatoid Renal Cell Carcinoma in Czechia

Total 247 results

Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (IO-PAZ)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Spain, Germany, United States, Austria, Czechia, United Kingdom, Argentina, Hungary, France, Canada, Chile
Pfizer

Terminated

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Czechia
National Cancer Institute (NCI)

Completed

Follow-Up Study of Kidney Cancer Patients

Renal Cancer

Czechia, Poland
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria
Millennium Pharmaceuticals, Inc.

Completed

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

Spain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
Mendus
TFS Trial Form Support; Accelovance

Completed

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA)

Renal Cell Carcinoma, Metastatic

United States, Spain, Czechia, Latvia, United Kingdom, Poland, Hungary, Sweden, France
Pfizer

Completed

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Metastatic Renal Cell Carcinoma

Czech Republic
Eisai Inc.

Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Metastatic Renal Cell Carcinoma

United States, Poland, United Kingdom, Spain, Czechia
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Renal Cell Cancer

Germany, Estonia, Russian Federation, Italy, United Kingdom, Netherlands, Greece, Switzerland, Finland, Lithuania, Sweden, Czech Republic
Argos Therapeutics

Terminated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Israel, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
Goethe University

Active, not recruiting

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Metastatic Renal Cell Carcinoma

Spain, Netherlands, United Kingdom, France, Germany, Belgium, Czechia
AVEO Pharmaceuticals, Inc.

Completed

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

Advanced Renal Cell Carcinoma

United States, Bulgaria, Canada, Chile, Czechia, France, Hungary, India, Italy, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom
AVEO Pharmaceuticals, Inc.

Completed

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)

Advanced Renal Cell Carcinoma

United States, Argentina, Bulgaria, Canada, Chile, Czechia, France, Hungary, India, Italy, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom
GlaxoSmithKline

Completed

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Taiwan, Belgium, Israel, Australia, Hong Kong, China, Czech Republic
University Hospital Ostrava

Completed

Prognostic Immune Biomarkers in HNSCC

Head and Neck Cancer | Squamous Cell Carcinoma

Czechia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, Israel, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, Sweden, Ta... and more
Centocor, Inc.

Completed

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

France, United Kingdom, Netherlands, Czech Republic
Tracon Pharmaceuticals Inc.

Terminated

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Hungary, Czechia, United Kingdom
University Hospital Ostrava

Completed

Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma (HNSCC)

Squamous Cell Carcinomas of the Head and Neck

Czech Republic
Novartis Pharmaceuticals

Completed

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada, France, Italy, Spain, Belgium, Germany, Hungary, Saudi Arabia, Netherlands, Switzerland, Australia, Austria, Poland, Sweden, United Kingdom, Thailand, Korea, Republic of, Greece, Israel, Argentina, Japan, Colo... and more
Novartis Pharmaceuticals

Completed

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

Cancer | Renal Cell Carcinoma (RCC)

United States, Belgium, Canada, Spain, United Kingdom, Turkey, Austria, Argentina, Brazil, Czechia, France, Germany, Israel, Italy, Poland, Russian Federation, Korea, Republic of, Chile, China, Greece, Hungary, Ireland, Slovakia, Japan, Denmar... and more
Exelixis

Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Non-Clear Cell Renal Cell Carcinoma

United States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Ipsen

Completed

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma (CASSIOPE)

Renal Cell Carcinoma

Germany, Spain, Italy, Greece, Belgium, France, Netherlands, United Kingdom, Austria, Czechia, Poland
Hoffmann-La Roche

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

Renal Cell Carcinoma

United States, Spain, Czechia, United Kingdom, Romania, France, Italy, Germany, Poland
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
University Hospital Ostrava

Recruiting

SBRT/RT in Oligometastatic Stage IV NSCLC

Non Small Cell Lung Cancer

Czechia
University Hospital Ostrava

Recruiting

Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Czechia
Novartis Pharmaceuticals

No longer available

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Metastatic Renal Cell Cancer

United States, United Kingdom, Czech Republic, Canada, Germany, Lebanon, Turkey, Hungary, Norway, Australia, Austria, Belgium, Switzerland
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151)

Renal Cell Carcinoma

Korea, Republic of, United States, France, Italy, United Kingdom, Canada, Australia, Brazil, Denmark, Spain, Turkey, Japan, Czechia, Singapore, Thailand, Taiwan, Russian Federation, Germany, Bosnia and Herzegovina, Poland, Mexico
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Carcinoma, Renal Cell

Poland, Australia, Japan, United States, Korea, Republic of, Taiwan, China, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Romani... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Carcinoma, Renal Cell

United States, Colombia, Canada, Australia, Finland, Japan, United Kingdom, Brazil, Chile, China, Croatia, Czechia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Norway, Philippines, Polan... and more
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)

Renal Cell Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Singapore, Spain, Taiwan, United...
GlaxoSmithKline

Completed

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, Argentina, Korea, Republic of, Estonia, Hong Kong, Ukraine, Ireland, Latvia, Pakistan, China, Austria, Greece, New Zealand, Poland, Russian Federation, United Kingdom, Australia, India, Czech Republic, Mexico, Brazil, Chile, ... and more
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
Pfizer

Completed

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC)

Kidney Neoplasms | Carcinoma, Renal Cell

United States, Australia, Netherlands, Canada, Czech Republic, Poland, Russian Federation, Slovakia, Sweden, Turkey, Ukraine, Serbia, Italy, Spain, United Kingdom, Greece, Taiwan, Argentina, Mexico, Latvia, Hungary, Former Serbia... and more
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Pfizer

Approved for marketing

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Netherlands, Canada, Bulgaria, Czech Republic, Hungary, Spain, United Kingdom, Greece, Australia, Belgium, France, Germany, Italy, Panama, Russian Federation, Sweden, Brazil, Taiwan, Argentina, Mexico, Serbia, Thailand, Korea, Republic of and more
Novartis Pharmaceuticals
Roche Pharma AG

Completed

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adenocarcinoma | Carcinoma | Renal Cell | Nephroid Carcinoma | Hypernephroid

Belgium, Italy, Spain, United Kingdom, Germany, Taiwan, Turkey, Egypt, Hong Kong, Russian Federation, Switzerland, Thailand, France, Netherlands, Korea, Republic of, Brazil, United States, Czech Republic, South Africa, Hungary, ...
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Renal Cell Cancer

Italy, Spain, Germany, Switzerland, Russian Federation, Czech Republic, France, United Kingdom, Belgium, Singapore, Hungary, Poland, Israel, Taiwan, Australia, Finland, Netherlands, Norway
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Renal Cell Carcinoma

Spain, Canada, Portugal, Korea, Republic of, Taiwan, United States, Netherlands, United Kingdom, Czechia, Italy, Finland, Greece, Romania, Australia, Poland, Russian Federation
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Renal Cell Carcinoma

France, Spain, Chile, United States, Argentina, Austria, Czechia, Greece, Italy, Mexico, Poland, Portugal, Romania, Russian Federation
Novartis Pharmaceuticals

Active, not recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Renal Cell Carcinoma | Colorectal Cancer | Gastroesophageal Cancer

United Kingdom, Australia, Belgium, Germany, Italy, Taiwan, Czechia, Israel, Spain, Japan, Singapore, Canada, Korea, Republic of, United States, Chile
Novartis Pharmaceuticals

Active, not recruiting

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Carcinoma, Renal Cell

Spain, Singapore, Czechia, Italy, Japan, France, United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
AVEO Pharmaceuticals, Inc.

Completed

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

United States, Hungary, Spain, United Kingdom, Italy, Germany, France, Belgium, Czechia, Canada, Denmark, Poland

Clinical Trials on Sarcomatoid Renal Cell Carcinoma in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations